External link, please review our disclaimer.

Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA)

What We Do:

The DPMCDA plans and directs studies necessary to identify, evaluate, and develop medications to treat substance use disorders (SUDs). The Division develops and administers a program of basic and clinical research to develop innovative pharmacological (both chemical and biological) approaches to treat SUDs . This program is implemented through collaborations with academia, industry (pharmaceutical and biotechnology companies), and other government institutions (e.g., the Veterans Administration and the FDA). The Division also coordinates and provides leadership in the area of medical conditions associated with SUDs, including but not limited to HIV/AIDS.

Research Programs:

From concept to medication to treatment graphic

Division Listings:

Staff Listings:

Mailing Address:

Division of Pharmacotherapies & Medical Consequences of Drug Abuse
National Institute on Drug Abuse
6001 Executive Boulevard
Room 4123, MSC 9551
Bethesda, MD 20892-9551
(301) 443-6173 (phone)
(301) 443-2599 (fax)

This page was last updated December 31, 2011.

Featured Publication

Featured Publication

Drugs, Brains, and Behavior - The Science of Addiction

As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site